Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature

Keyphrases

• Adverse Event Rates 80%
• Adverse Event Reporting 20%
• Adverse Events 100%
• Albendazole 60%
• Anthelmintic 20%
• Arthralgia 20%
• Clinic-based 20%
• Clinical Trials 20%
• Community Treatment 20%
• Community-based Study 40%
• Diethylcarbamazine 80%
• Dose Combination 20%
• Fever 20%
• Global Programme to Eliminate Lymphatic Filariasis 20%
• Headache 20%
• Hospital-based 20%
• Inclusion Criteria 20%
• Infection Rate 20%
• Ivermectin 80%
• Lymphatic Filariasis 100%
• Malaise 20%
• Mass Drug Administration 40%
• MEDLINE 20%
• Microfilaraemia 40%
• Microfilaria 20%
• Moderate to Severe 20%
• Myalgia 20%
• Ovid 20%
• Safety Trial 20%
• Single-dose Treatment 100%
• Systemic Side Effects 20%
• Treatment Group 20%
• Treatment Study 20%
• Treatment-related Adverse Events 20%
• Triple Therapy 20%
• Two-drug Regimen 20%
• Uniform Approach 20%

Medicine and Dentistry

• Adverse Event 100%
• Albendazole 27%
• Arthralgia 9%
• Clinical Trial 9%
• Diethylcarbamazine 36%
• Drug Administration 18%
• Drug Therapy 27%
• Group Therapy 18%
• Headache 9%
• Infection Rate 9%
• Ivermectin 36%
• Lymphatic Filariasis 100%
• Malaise 9%
• Microfilariasis 18%
• Myalgia 9%
• Single Drug Dose 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Albendazole 27%
• Anthelmintic Agent 9%
• Arthralgia 9%
• Clinical Trial 9%
• Diethylcarbamazine 36%
• Drug Administration 18%
• Headache 9%
• Infection Rate 9%
• Ivermectin 36%
• Lymphatic Filariasis 100%
• Malaise 9%
• Microfilaria (Nematode Larva) 9%
• Microfilariasis 18%
• Myalgia 9%
• Pharmacotherapy 9%